Development and Application of Chronic Disease Risk Prediction Models by 源��쁽李� & �삤�꽑誘�
Yonsei Med J   http://www.eymj.org   Volume 55   Number 4   July 2014 853
Development and Application of  Chronic Disease Risk 
Prediction Models
Sun Min Oh,1,2 Katherine M. Stefani,3 and Hyeon Chang Kim1,4
1Department of Preventive Medicine, Yonsei University College of Medicine, Seoul; 
2Medical Affairs, Novartis Korea Oncology, Seoul;
3Department of Research Affairs, Yonsei University College of Medicine, Seoul;
4Cardiovascular and Metabolic Diseases Etiology Research Center, Yonsei University College of Medicine, Seoul, Korea.
Received: April 3, 2014
Corresponding author: Dr. Hyeon Chang Kim,  
Department of Preventive Medicine, 
Yonsei University College of Medicine,
50-1 Yonsei-ro, Seodaemun-gu, 
Seoul 120-752, Korea.
Tel: 82-2-2228-1873, Fax: 82-2-392-8133
E-mail: hckim@yuhs.ac
∙ The authors have no financial conflicts of 
interest.
© Copyright:
Yonsei University College of Medicine 2014
This is an Open Access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Currently, non-communicable chronic diseases are a major cause of morbidity and 
mortality worldwide, and a large proportion of chronic diseases are preventable 
through risk factor management. However, the prevention efficacy at the individu-
al level is not yet satisfactory. Chronic disease prediction models have been devel-
oped to assist physicians and individuals in clinical decision-making. A chronic 
disease prediction model assesses multiple risk factors together and estimates an 
absolute disease risk for the individual. Accurate prediction of an individual’s fu-
ture risk for a certain disease enables the comparison of benefits and risks of treat-
ment, the costs of alternative prevention strategies, and selection of the most effi-
cient strategy for the individual. A large number of chronic disease prediction 
models, especially targeting cardiovascular diseases and cancers, have been sug-
gested, and some of them have been adopted in the clinical practice guidelines and 
recommendations of many countries. Although few chronic disease prediction 
tools have been suggested in the Korean population, their clinical utility is not as 
high as expected. This article reviews methodologies that are commonly used for 
developing and evaluating a chronic disease prediction model and discusses the 
current status of chronic disease prediction in Korea.
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INTRODUCTION
Annually, 36 million deaths (more than two-thirds of total deaths in the world) 
are caused by non-communicable chronic diseases (NCDs) including cardiovas-
cular diseases (17.3 million deaths), cancers (7.6 million), chronic respiratory dis-
eases (4.2 million), and diabetes (1.3 million).1 In high-income countries, the 
health care burden of NCDs remains high; however, the death rates of NCDs 
have been decreasing over the last few decades.2 For example, the age-adjusted 
mortality for coronary heart disease decreased by more than 50% between 1980 
and 2000 in the U.S.3 The prevention and management of major risk factors con-
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HOW TO DEVELOP CHRONIC DISEASE 
RISK PREDICTION MODELS
Identifying risk predictors
Chronic disease risk prediction models use multiple covari-
ates to estimate the probability of having or developing a 
certain chronic disease within a specific time period.8-10 Re-
liable data must be secured to develop the risk prediction 
model so that potential risk factors (or predictors), disease 
outcomes, and their associations may also be evaluated. 
The most reliable data comes from prospective cohort stud-
ies since the risk factors and their contributions to the dis-
ease incidence can be evaluated. Data from retrospective 
cohort studies are also frequently used to develop risk pre-
diction models.10 Retrospective cohort data can save time 
and decrease costs, but these data are documented usually 
for health screening or administrative purposes. Therefore, 
limited information on covariates and disease outcomes 
might affect the performance of the prediction model. Data 
from case-control studies are generally not reliable for pre-
diction model development, but data from nested case-con-
trol or case-cohort designs within an established cohort can 
be successfully used.10 Moreover, suspected outcomes such 
as disease events or deaths should be ascertained using med-
ical records and/or death certificates. Candidate risk predic-
tors may include variables related to demographics, medical 
history, family history, physical examinations, and bio-
markers. These variables should be measured by standard-
ized methods, and the validity and reliability of the mea-
surements should be evaluated regularly over the study 
period. Among the evaluated variables, potential risk pre-
dictors could be selected based on the literature and statisti-
cal investigation of the study dataset. 
Developing candidate risk prediction models
Multiple linear regression, multiple logistic regression, and 
Cox’s proportional hazard regression models are employed 
frequently to quantify the contribution of each covariate 
(predictor) on the development of a new event (the disease 
of interest). After potential risk predictors and disease out-
comes are selected, the strength of the association (regres-
sion coefficients) between the covariates at baseline and the 
incident event is estimated using an appropriate statistical 
model. If risk factors were measured repeatedly during the 
follow-up period, the predictive performance may be im-
proved by including updated values or considering time-
tributed to a 44% reduction in coronary heart disease mor-
tality, while treatments contributed 47% to the reduced 
mortality.4 Smoking cessation is the largest contributing 
factor to the reduced lung cancer mortality;5 however, the 
prevalence of smoking has substantially decreased in most 
high-income countries.2 In most low- and middle-income 
countries, NDCs are now the leading causes of death, and 
the burden of NCD is increasing rapidly in low-income 
populations.1 Annually, 80% of NCD deaths and 90% of 
premature NCD deaths (before the age of 60) occur in low- 
and middle-income countries.1 In Korea, cancer, cardiovas-
cular diseases, chronic respiratory diseases and diabetes are 
the four main NCDs that are among the top 10 causes of 
death, and these NCDs account for more than 60% of all 
deaths in 2012.6 In Korea, unlike other high-income coun-
tries, the death rates of most NCDs have been increasing or 
plateauing over the past few decades.6 Moreover, the health 
care burden of NCDs is expected to steeply increase with a 
rapidly aging Korean population. Thus far, efforts to pre-
vent NCDs have been mainly invested at the population 
level, such as through mass health screenings and cam-
paigns for smoking cessation, reducing alcohol abuse, en-
couraging a healthy diet, and exercise. Although this kind 
of population-based approach has greatly improved NCD 
prevention, personalized medical care is also important to 
assess disease risk and preventive strategies at an individual 
level. 
Epidemiological research contributed much to NCD pre-
vention by identifying major risk factors and by evaluating 
the performance of screening, diagnosis, and treatment mo-
dalities. Traditional epidemiologic studies measure the im-
pact of a risk factor on a certain disease by calculating rela-
tive risk and odds ratios.7 However, these measures of risk 
are difficult to apply at an individual level because an indi-
vidual may have a disease without any exposure to risk fac-
tors or may be exposed to multiple risk factors at various 
exposure levels.7 Therefore, in the clinical decision-making 
process, absolute disease risk should be estimated for each 
individual.7 Disease risk prediction (or health risk appraisal) 
models have been developed to assess the impact of multi-
ple risk factors together for the estimation of an individual’s 
absolute disease risk.7 The development of risk prediction 
models is a very active area of research where epidemio-
logic findings are translated into clinical applications. If an 
individual’s future risk for certain diseases can be predicted, 
then efficient and personalized treatment strategies can be 
chosen.
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if adding a new predictor or replacing an existing model 
with a new one improves an individual’s risk stratification. 
Additionally, reclassification tables are constructed sepa-
rately for participants with and without events to calculate 
the net reclassification improvement (NRI), an index of im-
trend of the risk factors. Moreover, competing risks of de-
veloping other diseases may also be considered, especially 
for models that predict long-term or lifetime disease risk.11,12 
Once regression coefficients are calculated, they can be mul-
tiplied and rounded off as integers to simplify the model.
Evaluating the performance of the risk prediction model
To find the most effective risk prediction model, multiple 
candidate models that include a different combination of 
the selected risk factors should be evaluated in diverse as-
pects: global model fitness, discrimination, calibration, and 
reclassification.10,13 First, global model fitness is measured 
to find the best-fit model with the least number of covari-
ates. Among the various measures of global model fitness, 
the Akaike Information Criterion and the Bayes Informa-
tion Criterion are the two commonly used methods.13,14 
Second, discrimination refers to the ability to separates 
those with events from those without events. Receiver op-
erating characteristics (ROC) curves are commonly used 
for evaluating discrimination performance.15,16 The ROC 
curve is a plot of sensitivity on the y-axis and 1-specificity 
on the x-axis for all possible cut-off values. The values of 
area under the ROC curve (AUC) and C-statistic should 
fall between 0.5 and 1.0 with a high score indicating a high 
power of discrimination (Fig. 1). AUC scores of 0.70 to 
0.80 are considered an acceptable range of discriminative 
power, and a score of 0.80 or higher is considered to indi-
cate excellent model discrimination.17 
Third, calibration is a measure of how accurately the pre-
dicted probabilities of developing a disease match the subse-
quently observed event rate. The most common approach is 
comparing predicted and observed disease rates across dis-
ease different risk groups. The study population is then di-
vided into multiple risk categories (often deciles) according 
to the predicted risk. Then, the predicted and observed event 
rates in each category are graphically compared. Fig. 2 
shows an example of a good and poor calibration perfor-
mance. Smaller differences between predicted and observed 
rates indicate better model calibration. The statistical signif-
icance of the difference between predicted and observed rates 
is often assessed by the Hosmer-Lemeshow’s chi-square 
test.17 The Brier score, which is the sum of the squared differ-
ence between the observed outcome and fitted probability, is 
a measure of fit that considers both calibration and discrim-
ination.14 
Fourth, reclassification tables are commonly used to 
compare a new model with an existing model to determine 
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Fig. 1. Simluated receiver operating characteristics curves for two predic-
tion models. AUC, area under the receiver operating characteristics curve.
Fig. 2. Simulated calibration charts for two prediction models: one with 
good calibration performance (A) and the other with poor calibration per-
formance (B). 
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two models predict disease risk for each individual. With 
adding lines indicating cut-off points for risk classification, 
the plot can show who are to be reclassified into a different 
category when we replace the old prediction model with a 
new one.7,13
Validating the risk prediction model
When a new risk prediction model is developed, it needs to 
be validated in a dataset independent of the dataset that has 
been used to develop the model. Validating and updating (if 
needed) the developed model are important because, with-
proved risk stratification. These tables quantify the correct 
and incorrect movements of participants into specific cate-
gories after applying the new prediction model.18 Any par-
ticipants with an event who moved upward (reclassified 
into higher risk categories) or without an event who moved 
downward (reclassified into lower risk categories) indicate 
that a correct reclassification has been made. On the con-
trary, any downward movement for participants with an 
event or upward movement for participants without an 
event implies that an incorrect reclassification was made. 
The NRI is calculated as the difference of the proportion of 
patients correctly classified minus that of those incorrectly 
classified (Table 1).18 
NRI=[p(up|D=1)-p(down|D=1)]-[p(up|D=0)-p(down|D=0)]   
(D represents an event; 1 for event, 0 for non-event)
The integrated discrimination improvement (IDI) index 
is another reclassification tool that calculates the new mod-
el’s ability to improve integrated sensitivity without sacri-
ficing integrated specificity.18 
IDI=(ISnew-ISold)-(IPnew-IPold)
(IS; integrated sensitivity, IP; integrated specificity)
Moreover, bar graphs and scatter plots can be employed 
to depict the predictive performance of the developed mod-
el in diverse aspects.7 Fig. 3 is a simulated scatter plot com-
paring the performance of two prediction models. Vertical 
and horizontal axes indicate the risks predicted by an old 
model and a new model, respectively. The red dots are those 
with an event of interest, and the blue open circles are those 
without event. This plot visually displays how closely the 
Table 1. Simulated Reclassification Tables Comparing Two Prediction Models
New risk category
Low Intermediate High Total
Participants with an event
    Old risk category
        Low   30     50*       0*   80
        Intermediate      5† 130     70* 205
        High      0†      5† 110 115
        Total   35 185 180 400
Participants without an event
    Old risk category
        Low 390  130†      0† 520
        Intermediate     20* 190    40† 250
        High       0*     10*   20   30
        Total 410 330   60 800
Net reclassification improvement for those with the event: (50+70-5-5)/400=27.5%. Net reclassification improvement for those without the event: (20+10-
130-40)/800=-17.5%. Overall net reclassification improvement: (27.5%)+(-17.5%)=10.0%.
*People who are correctly reclassified when applying the new prediction model.
†People who are incorrectly reclassified when applying the new prediction model.
Fig. 3. Simulated scatter plot comparing the performance of two prediction 
models. Vertical axis indicates the risk predicted by an old model. Horizontal 
axis indicates the risk predicted by a new model. The red dots are those 
with an event of interest, and the blue open circles are those without event. 
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heart disease, brain infarction, intermittent claudication, and 
hypertensive heart failure.22 In this model, a multiple logis-
tic regression model was applied to obtain regression coef-
ficients of each risk factor, and a risk function score was de-
veloped with the coefficients of an efficient set of risk factors. 
Using this model, health care professionals identified per-
sons at a high CVD risk who need preventive treatment.22 
The Framingham Risk Score has been continuously devel-
oped and modified based on updated evidence. For exam-
ple, Cox’s proportional hazards regression analysis has 
been used to estimate an individuals’ 10-year total CVD 
risk as well as a specific CVD risk (for atrial fibrillation, 
coronary heart disease, congestive heart failure, diabetes 
mellitus, hypertension, and intermittent claudication).21,23 
Furthermore, a 30-year risk and lifetime risk of developing 
various CVDs have been suggested using advance statisti-
cal techniques to avoid bias in the assessment of true abso-
lute risk.12 
Even though the Framingham Heart Study results are 
fundamental evidence for the prediction of CVD risk, risk 
factors and the effect of risk factors on developing CVDs 
may differ by population. In fact, a study tested the Fram-
ingham Risk Score using the 2001 Korea National Health 
and Nutrition Examination Survey data, which is linked to 
the Korea National Health Insurance Corporation and is a 
representative population of non-institutionalized Kore-
ans.24 They reported that the Framingham model overesti-
mated the risk of ischemic heart disease (IHD) by 150% to 
320%.24 Thus, even a well-established risk prediction mod-
el such as the Framingham Risk Score requires frequent re-
calibration or adjustment for use in other populations in-
cluding the Korean population. More preferably, a CVD 
risk prediction model should be developed and validated 
using cohort data from the Korean population. One group 
of researchers in Korea has developed an IHD prediction 
model based on health screening and national health insur-
ance data, which is a representative population of Kore-
ans.25 Data are from biennial health screening tests between 
1992 and 1995 of civil servants, school teachers, and their 
spouses insured by the National Health Insurance Corpora-
tion.25 For outcome variables, deaths from IHD between 
1993 and 2002 were detected by linking the Cause of Death 
Statistics database from the Korea National Statistical Of-
fice, and hospital admissions for IHD between 1998 and 
2002 were identified using the National Health Insurance 
Corporation claim database.25 Among a total of 931467 par-
ticipants, a random sample of half of the population was 
out generalizability, the model may perform poorly in a real 
clinical setting. For validation, an internal or external datas-
et can be used. For internal validation, a study dataset is 
randomly divided into two subsets; one for developing and 
the other for validating the suggested model.19 Bootstrap-
ping, which repeatedly tests the model in the different ran-
dom subsets of the total dataset, is a preferred method for 
internal validation, especially when the study dataset is too 
small to be divided into development and validation sub-
sets.20 However, validating a model in an external dataset is 
desirable because by testing the new model in a more gen-
eralized population, the reliability of its performance can 
also be tested.19 Additionally, testing for temporal validation 
(using data from a different time period), geographical vali-
dation (using data from another geographic area), and do-
main validation (using data collected in a different setting) 
also provide information on the generalizability of the mod-
el.9,20 As was true for the development of the model, global 
model fitness, discrimination, calibration, and/or reclassifi-
cation analyses also need to be evaluated in the validation 
dataset.19 
EXAMPLES OF CHRONIC DISEASE  
RISK PREDICTION MODELS
Cardiovascular disease risk prediction models
The Framingham Risk Score is the most well-known ex-
ample of a health risk assessment model that assesses an in-
dividuals’ cardiovascular disease (CVD) risk and suggests 
lifestyle changes and/or early pharmacologic treatment for 
individuals. The Framingham Heart Study started with 5209 
Framingham residents between the ages of 30 and 62 in 
1948. The major aim of the original cohort was to secure 
epidemiological data on arteriosclerotic and hypertensive 
CVD, and successfully followed up these participants.21 
From 1960, major CVD risk factors including cigarette 
smoking, cholesterol level, blood pressure, physical inactiv-
ity, left ventricular hypertrophy, and glucose intolerance 
have been specified based on this cohort.21 The Framing-
ham Heart Study was expanded to the Offspring Cohort in 
1971, the Ommi cohort in 1994, the Third Generation Co-
hort in 2002, and the New Offspring Spouse Cohort and 
Second Generation Ommi Cohort in 2003 to reflect the di-
verse community in Framingham.21 After the 18 years of 
follow-up, a risk prediction model was developed to esti-
mate the 8-year risk of various CVDs including coronary 
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of breast biopsies showing atypical hyperplasia, and race or 
ethnicity.28 
Recently, a Korean breast cancer risk assessment tool 
was developed based on the modified Gail’s equation.29 
The study included 3789 sets of cases and controls from the 
Seoul Breast Cancer Study. In this population, the identified 
risk factors for women under the age of 50 were a family 
history of breast cancer in first-degree relatives, age at men-
arche, age at first full-term pregnancy, menopausal status, 
breastfeeding duration, oral contraceptive usage, and exer-
cise. Breast cancer incidence and mortality was calculated 
from the Korean National Cancer Registry and the Cause 
of Death Statistics from the Korea National Statistical Of-
fice, respectively. Individual probabilities of developing 
breast cancer were projected by combining information on 
an individual’s relative risk, baseline hazard rate, and com-
peting risk. The developed model was validated in two sep-
arate Korean cohorts; the AUC values were 0.61 in the Ko-
rean Multicenter Cancer Cohort and 0.89 in the National 
Cancer Center Cohort. This breast cancer risk assessment 
tool used the modified Gail model; however, the original 
Gail model was developed for women who participated in 
annual mammographic screening program, therefore fur-
ther adjustment in the Korean model is needed. Additional-
ly, because the study participants were Korean women who 
visited three teaching hospitals in Seoul for either breast 
cancer treatment or a community health screening, they 
may not represent the total population of Korean women. 
Therefore, this modified Gail model should be further vali-
dated in a representative, epidemiological cohort of Korean 
women.
CLINICAL APPLICATION
The health care burden of NCDs has been rapidly increas-
ing, but fortunately NCDs are preventable by managing 
risk factors.4,5 However, each individual is concomitantly 
exposed to multiple risk factors and at various exposure 
levels; therefore, tailored medical decisions are required to 
identify an individual’s disease risk and to provide person-
alized care. Validated, reliable NCD prediction models as-
sist healthcare professionals in the decision-making process 
by selecting candidates for intensive preventive interven-
tions or additional tests.30,31 For individuals, knowing their 
predicted risk increases their awareness of their chronic dis-
ease and the importance of prevention, helps to communi-
used to develop an IHD prediction model incorporating risk 
predictors of age, total cholesterol, systolic blood pressure, 
smoking, and diabetes.25 After development, the model was 
validated in the other half of the population by dividing risk 
of IHD into percentiles of 10 for predicted risk.25 The C-sta-
tistic, which shows the discriminatory power of the model, 
was 0.75 for men and 0.80 in women.25 This is the first IHD 
risk prediction model that was developed based on Korean 
data, but several limitations exist. Although the three datas-
ets employed to develop the model (data from health screen-
ings, cause of death statistics, and insurance claims) were 
collected nationwide, they were not originally constructed 
for research purposes. Therefore, available risk predictors 
were limited and the measurements were not fully stan-
dardized. Moreover, the causes of death and hospitalization 
records were not centrally adjudicated. Last, the clinical 
usefulness of this model in Korea is limited because most 
of the assessed individuals will fall into low-risk categories; 
therefore, individual preventative strategies cannot be de-
termined clinically. 
Breast cancer prediction models
Another example of a health risk assessment model is the 
Breast Cancer Risk Assessment Tool (Gail model) that helps 
to identify high-risk individuals among screened women. As 
a part of the Breast Cancer Detection Demonstration Proj-
ect, data from 2852 Caucasian women who were first diag-
nosed with breast cancer between 1973 and 1980 and 3146 
controls were used to calculate the relative risk for each risk 
factor and estimate probabilities of developing breast can-
cer.26 In this model, variables related to a family history of 
breast cancer in a first-degree relative, a late age at first 
childbirth, early menarche, and multiple previous benign 
breast biopsies were included.26 Ten years later, this model 
was validated in 5969 Caucasian women who were fol-
lowed up for 48.4 months and was found to provide useful 
information for women who plan to participate in regular 
mammographic screenings.27 Since its validation, it has 
been updated for atypical hyperplasia and to include Afri-
can Americans and Asian Americans using the Contracep-
tive and Reproductive Experiences Study and the Asian 
American Breast Cancer Study, respectively.28 The current 
model calculates a woman’s five-year and lifetime risk of 
developing breast cancer by accounting for age, age at men-
arche, age at the time of her first child’s birth (or if they have 
never given birth), family history of breast cancer (mother, 
sister, or daughter), number of past breast biopsies, number 
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breast cancer, and colorectal cancer are among the most fre-
quently predicted chronic diseases in Western countries; 
however these diseases are relatively uncommon in the Ko-
rean population. Although the incidence of these diseases is 
rapidly increasing in Korea, the currently measured inci-
dences are still lower than that of Western populations. 
Therefore, a majority of individuals fall into the low-risk 
group when their disease risk is assessed with a prediction 
model. Even with a disease prediction model that is validat-
ed in a Korean population, high-risk individuals who merit 
aggressive preventive treatment are difficult to identify. Fi-
nally, clinical practice guidelines and recommendations are 
not widely accepted in Korea as a method for disease pre-
vention.7 Assessing an individual’s disease risk has only 
limited clinical value because the predicted disease risk has 
little influence on the clinical decision-making process for 
chronic disease prevention.
FUTURE OF CHRONIC DISEASE 
PREDICTION 
A large number of disease prediction, risk assessment, and 
health risk appraisal tools have been developed and recom-
mended for general clinical use. However, their prediction 
accuracy and clinical utility vary widely. Moreover, there is 
little evidence supporting the idea that existing chronic dis-
ease prediction tools can improve clinical outcomes. Chron-
ic disease prediction models deemed relevant to the Korean 
population should be continuously developed, validated, up-
dated, and modified using prospective epidemiologic data. 
Newly suggested prediction models should be assessed ex-
tensively for their predictive power and clinical utility, and 
independent datasets should be employed when possible. 
These approaches require diverse community-based cohort 
studies with adequate sample size, follow-up length, and 
outcome adjudication. In the meantime, substantial efforts 
are required to improve risk communication, motivate phy-
sicians and individuals to execute preventative strategies, 
and develop clinical decision-making algorithms.
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cate their risk levels with others and their physicians, and 
motivates lifestyle modifications or adherence to treatment.30 
In the field of NCD prediction, developing an accurate 
and reliable prediction model is fundamental, yet other 
characteristics are required before the model can be deemed 
clinically useful. First, to use a NCD prediction model in 
broad range of populations with confidence, intensive mod-
el validation and continuous updates are required. Second, 
the model’s ease of use is also important. Physicians and in-
dividuals should have easy access to the model and be able 
to easily calculate disease risk as well as interpret the re-
sults to encourage widespread use. Finally, the results of the 
prediction model should be linked to clinical practice. The 
Gail model is a good example of a clinically useful NCD 
prediction tool, and the modified Gail model has been ex-
tensively validated and updated worldwide. Both models 
are easily accessible to physicians and their patients to cal-
culate breast cancer risk. For example, when a five-year 
breast cancer risk of 1.66 percent or higher is calculated by 
the modified Gail model, the patient is advised to begin 
preventive chemotherapy to reduce breast cancer risk.32 
Thus, the modified Gail model continues to be widely used 
in daily clinical practice.
The clinical utility of a disease prediction model can be 
population specific because the baseline disease risk, sub-
type distribution of the disease, and exposure levels to risk 
factors differ by region and ethnicity. Several chronic dis-
ease risk prediction models have been suggested for use in 
the Korean population,29,32-36 but have not been employed as 
frequently as expected. One reason for this could be that 
most of the prediction models have not been thoroughly 
validated in other independent datasets. Validation requires 
diverse community-based cohort studies to be used, but 
these kinds of data are not yet available in Korea. Although 
a considerable number of cohort studies have started over 
the last few decades in Korea, most lack a standardized 
process of outcome ascertainment and adjudication. Also, 
the more recent cohort studies are not suitable for use as a 
validation dataset because the follow-up period is short and 
only a small number of outcomes have been observed. Thus, 
it is currently not possible to validate a disease prediction 
model using various independent datasets in Korea. To 
maximize the clinical utility of disease prediction models, a 
wealth of epidemiological data from the Korean population 
is required. Furthermore, existing cohort studies should al-
locate more resources to improve the process of outcome 
ascertainment and adjudication. Ischemic heart disease, 
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